HAIFA, Israel, Dec. 1, 2009 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT) today announced that it has completed dosing of the first of three dosage groups of patients in Europe with its placenta-derived cell therapy product, PLX-PAD, in a Phase I dose-escalating clinical trial for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).
